I kliniske forsøg af monoterapi med oral topotecan til patienter med recidiverende småcellet lungecancer var den dosisbegrænsende toksicitet hæmatologisk.
In clinical trials involving patients with relapsed small cell lung cancer, the dose limiting toxicity of oral topotecan monotherapy was found to be haematological.